CED Clinical Trials in Houston, Texas
261 recruitingHouston, Texas
Showing 1–20 of 261 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 1Phase 2
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Locally Advanced Solid Tumor
Tango Therapeutics, Inc.225 enrolled26 locationsNCT05732831
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled32 locationsNCT06638307
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 1Phase 2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1Phase 2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+12 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT04090567
Recruiting
Phase 1
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Ovarian CancerAdvanced Solid TumorsBreast Cancer Recurrent+1 more
Accent Therapeutics90 enrolled5 locationsNCT06799065
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Lung CancerAdvanced Solid TumorMetastatic Solid Tumor+2 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Exelixis429 enrolled16 locationsNCT05932862
Recruiting
Phase 1Phase 2
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Advanced Solid Tumors
Eikon Therapeutics130 enrolled10 locationsNCT06907043